{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:14:16Z","timestamp":1794006856987,"version":"4.8.0"},"reference-count":7,"publisher":"SAGE Publications","issue":"8","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Mult Scler"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:p>The Cambridge Centre for Myelin Repair One (CCMR-One) trial showed that 6\u2009months of bexarotene reduces visual evoked potential (VEP) latency in people with relapsing-remitting multiple sclerosis (MS). In a single-centre follow-up study of these participants, we re-examined full-field VEP and clinical assessments. Twenty participants (12 bexarotene and 8 placebo) were seen on average 27\u2009months after their trial involvement. In an analysis of all eyes with recordable signal (24 bexarotene and 14 placebo), the adjusted bexarotene-placebo treatment difference in P100 latency was \u22127.79 (95% confidence interval (CI)\u2009=\u2009\u221214.76, \u22120.82) ms, p\u2009=\u20090.044. We conclude that there were durable improvements in VEP latency, suggesting long-term benefits from exposure to a remyelinating drug.<\/jats:p>","DOI":"10.1177\/13524585241233177","type":"journal-article","created":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T06:49:11Z","timestamp":1709275751000},"page":"1066-1071","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":8,"title":["Bexarotene leads to durable improvements in visual evoked potential latency: A follow-up study of the Cambridge Centre for Myelin Repair One trial"],"prefix":"10.1177","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8710-0930","authenticated-orcid":false,"given":"Christopher E","family":"McMurran","sequence":"first","affiliation":[{"name":"Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trisha","family":"Mukherjee","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7737-5834","authenticated-orcid":false,"given":"J William L","family":"Brown","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurosciences, University of Cambridge, Cambridge. UK\/NMR Research Unit, Queen Square Multiple Sclerosis Centre, University College London (UCL) Institute of Neurology, London. UK\/Clinical Outcomes Research (CORe) Unit, The University of Melbourne, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alasdair J","family":"Coles","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7562-2838","authenticated-orcid":false,"given":"Nick G","family":"Cunniffe","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,3,1]]},"reference":[{"key":"bibr1-13524585241233177","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00179-4"},{"key":"bibr2-13524585241233177","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32346-2"},{"key":"bibr3-13524585241233177","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(16)30377-5"},{"key":"bibr4-13524585241233177","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30140-X"},{"key":"bibr5-13524585241233177","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-019-09421-x"},{"key":"bibr6-13524585241233177","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.33.11.1444"},{"key":"bibr7-13524585241233177","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.94.15_supplement.1599"}],"container-title":["Multiple Sclerosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13524585241233177","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/13524585241233177","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13524585241233177","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T04:14:31Z","timestamp":1777695271000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/13524585241233177"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,1]]},"references-count":7,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.1177\/13524585241233177"],"URL":"https:\/\/doi.org\/10.1177\/13524585241233177","relation":{},"ISSN":["1352-4585","1477-0970"],"issn-type":[{"value":"1352-4585","type":"print"},{"value":"1477-0970","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,1]]}}}